SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                           CURRENT REPORT ON FORM 8-K

                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934




                         Date of Report: April 16, 1997
                        (Date of Earliest event reported)


                         *******************************


                          MEDIZONE INTERNATIONAL, INC.

             (Exact name of Registrant as specified in its charter)




          Nevada              2-93277-D                87-0412648
          State of            Commission               IRS Taxpayer
          Incorporation       Registration             No. I.D. Number




            123 East 54th Street, Suite 7B, New York, New York 10022
            ---------------------------------------------------------
                     Address of Principal executive offices


                  Registrant's telephone number: (212) 421-0303





Item 5.  Other Events

1.       Relationship with JRH Biosciences, Inc.

     By  letter  dated  April  16,  1997,  Medizone  International,   Inc.  (the
"Company") and JRH Biosciences, Inc. ("JRH"), located in Lenexa, Kansas, entered
into an agreement whose objective is to investigate the commercial applicability
of the Company's viral  inactivation  technology (the "Process") to treat bovine
serum  manufactured  by JRH and its  affiliate,  Filtron Pty Ltd., of Melbourne,
Australia, with a view to licensing the Process to JRH.

     Pursuant to this letter, during the initial stage, JRH will investigate the
application of the Process at the lab bench level at its Lenexa, Kansas facility
and  evaluate the Process'  ability to maintain  the  bio-performance  of bovine
serum subsequent to treatment with ozone,  while exhibiting a sufficient  degree
of viral  inactivation.  The Company is to provide the hardware  (i.e. the ozone
generator-monitor-dosimeter)   to   be   utilized   in   connection   with   the
investigation.  The  period for this  investigation  is  projected  to be twelve
months  (the "Stage I Period"),  during this  period,  the Company may not enter
into any  arrangements  with any other party in connection  with the  commercial
applicability  of the Process with respect to the treatment of bovine serum.  If
JRH is  satisfied  with the results of this initial  stage,  it may enter into a
subsequent agreements, pursuant to which it is envisioned that the parties would
(i)  collaborate on developing a commercially  viable device for the application
of the  Process to bovine  serum and (ii) enter into  agreements  to license the
Company's technology to JRH for the inactivation of viral contaminants in bovine
serum on mutually agreed to terms.

     JRH may discontinue its participation in this arrangement  during the Stage
I Period at any time,  without  penalty.  In the event JRH does  discontinue its
participation  during  the Stage I Period,  the  Company  may enter  into  other
relationships for the purpose of treating bovine serum, provided,  however, that
JRH will be provided with notice of such new  relationships  and,  under certain
circumstances,  will be  permitted  to  reinstate  its research and exclude such
other new  relationship  on the part of the Company on one  occasion  during the
initial twelve month period.

                                       2




2.  Appointment of Chief Executive Officer - Corporate

     On April 30, 1997, the Company appointed Arthur P. Bergeron to the position
of Chief  Executive  Officer -  Corporate.  Mr.  Bergeron,  who will remain Vice
President and Chief  Financial  Officer of the Company,  will report directly to
the  Company's  Board of Directors  and will be in charge of the  administrative
aspects of the Company's operations, including the day-to-day general management
of the Company and its corporate finance aspects.

                                       3



                                   SIGNATURES

     Pursuant to the  requirements of the Securities Act of 1934, the Registrant
has  duly  caused  this  Current  Report  to be  signed  on  its  behalf  by the
undersigned, one of its officers thereunto duly authorized.

Dated:  New York, NY
        May 5, 1997

                                                   MEDIZONE INTERNATIONAL, INC.



                                                   By: s/Joseph S. Latino
                                                       ------------------
                                                       Joseph S. Latino
                                                       President

                                       4









                                  EXHIBIT 10TT



                   Agreement between Medizone International,
                   Inc. and JRH Biosciences, Inc., dated April
                   16, 1997.







April 16, 1997


Dr. Karen Etchberger
JRH Biosciences
13804 W. 107th Street
Lenexa, KS  66215

Fax # (913) 469-5584


Dear Karen,

Based upon our latest  conversation of April 1, 1997 and the  correspondence  to
date, I am pleased to confirm  that you wish to proceed  with the  project.  The
following  outlines  the  framework  of the  strategic  partnership  between JRH
Biosciences and Medizone International, Inc. Execution of this agreement by both
JRH Biosciences and Medizone  International,  Inc. shall constitute  approval of
the contents  herein.  The agreement  has been  subdivided  into three  separate
Stages  (I,  II and III)  each  requiring  separate  documentation  but  focuses
primarily on Stage I (Ia and Ib) as defined below.  However, the general purpose
and  descriptions  for Stages II and III as defined herein are prefaced with the
proviso that prior stage success and JRH  Biosciences'  explicit  decision to go
forward to the next stage are requisite (see Go/no go option).

Objective: To license Medizone International,  Inc.'s ("MII") viral inactivation
technology  ("process") to JRH for the specific  application of treating  bovine
serum manufactured at JRH BioSciences  ("JRH"),  Lenexa,  Kansas and Filtron Pty
Ltd., Melbourne, Australia.

Plan: Three major stages are envisioned towards licensing this process.  Stage I
is broken into two sections;  the first (Ia) being the biological performance of
post-treated  serum, and the second (Ib) being the viral  inactivation  kinetics
with model viruses at conditions  established  in the  bio-performance  section.
Stage II represents a "scale-up" analysis to determine the most effective device
to be  designed  that  will  accommodate  JRH's  production  volume  (i.e.  1200
liters/day)  and  the  manufacture  of  said  device.  Stage  III is the  actual
licensing  process that will be based on a number of factors,  including but not
limited to: market share,  degree of subsidization of "scale-up" and development
costs, etc. Successful completion of each Stage, or subdivision, is necessary to
move on to the next level of investigation.





In  addition,  MII  will  not  enter  into  any  arrangement(s)  for  commercial
applicability of the process with any other parties with respect to treatment of
bovine serum prior to JRH completing  Stage I as proposed herein or for a period
of twelve (12) months,  whichever is shorter.  This period of twelve (12) months
permits for an initial three (3) month period of  acclimation  to the process by
JRH personnel,  with the nine (9) month balance being the time period  projected
to complete  both Stages Ia and Ib. JRH  reserves the right to  discontinue  the
project at any period  within  Stage I (Go/no go option).  In the event that JRH
decides not to proceed at any stage, MII would retain sole ownership of the data
generated to the point of  discontinuance of the project.  Upon  discontinuance,
MII would be permitted to enter into discussions with any entity for the express
purpose of treating bovine serum.  Prior to entering into a formal  relationship
with any entity for the purpose of treating bovine serum,  MII would provide JRH
notice of its intent and offer three (3) business  days for JRH to  re-institute
the research  from the point of  discontinuance.  In the event that JRH does not
chose to reinstitute the research,  all data generated  between JRH and MII from
commencement  of the  partnership  to  the  point  of  discontinuance  would  be
delivered  to MII  for its  use at the  discretion  of  MII.  This  scenario  of
restarting the program after  discontinuance  by JRH is for one time only, after
which any discontinuance renders all data the sole property of MII.

MII agrees that after the twelve  (12) month  period has  elapsed,  it would not
enter into any commercial  arrangement with other parties that would effectively
exclude a commercial agreement with JRH unless the proposed three stage research
program was stopped short of completion by either party.

Despite  the  foregoing,  MII is not  prevented  from  entering  into any  other
relationships,  research or  otherwise,  with any party in this field insofar as
the treatment material is not bovine serum.

During the period  that JRH  evaluating  MII's  process,  any new  technological
developments  or advances  by MII would be afforded to JRH it solely  applies to
the  treatment of bovine  serum.  Any new  technological  developments  that are
developed  in the scope of the JRH  evaluation  and  outside  the scope of MII's
present  patent  coverage  would be owned solely by MII but would be afforded to
JRH for their use in the treatment of bovine serum only.

Stage I Objective:  To investigate  the  application of MII's process at the lab
bench level in JRH's  facility in Lenexa,  Kansas and to evaluate  the  process'
ability to maintain  bioperformance  subsequent  to  treatment  (Stage Ia) while

                                       2




exhibiting a sufficient degree of viral  inactivation  (Stage Ib). Upon entering
into    this     partnership,     MII    will    provide     hardware     (ozone
generator-monitor-dosimeter), disposables, and technical expertise necessary for
JRH to perform and complete these investigations.

Ia   Studies as listed below will be performed by JRH to determine  the level of
     bio-performance  exhibited by serum  treated with MII's process as compared
     to  untreated  serum.  Biological  performance:  Multiple  passage  (three)
     passage growth assay on six different cell lines, plating efficiency on two
     cell lines with multiple serum  concentrations,  cloning  efficiency of one
     cell line,  MTT  growth  assay on three  cell  lines  with  multiple  serum
     concentrations,   IgG  production  and  biochemical  profile;  Satisfactory
     results  will be defined as  expressing  > 75% of  control  values  (non- -
     treated serum from the same lot as the treated material).

as   Electrophoretic profile: Satisfactory results are defined as the expression
     of no  additional  or missing  bands by the  treated  serum as  compared to
     control, non-treated serum

Ib   Studies as listed  below  will be  performed  by JRH on serum  artificially
     spiked with a number of model  pathogens to  determine  the degree of viral
     inactivation   exhibited  by  MII's  process  under  treatment   conditions
     previously defined in Stage Ia.

         - Bacteria, yeast and mycoplasma:  detectable absence
           satisfactory
         - Viruses and phage 6 log reduction is satisfactory

         Pathogens:

         E. coli                             Bovine viral diarrhea
         B. pumilus                          Parainfluenza type 3
         C. albicans                         Infectious bovine rhinotracheitis
         Acholeplasma laidlawii              Porcine parvovirus
         JH Strauss                          Minute virus of mice

Based upon continued  success,  it is mutually  expected that this  relationship
between  MII and JRH  will  result  in  either  a  licensing  or  joint  venture
agreement; the terms and conditions of which are to be mutually agreed to by JRH
and MII.  Regardless  of format or structure,  the terms and  conditions of such
licensing are to be finalized prior to the inception of Stage IIb.

Upon successful  completion of Stage I and with consideration to the proviso set
forth in the Go/no go option, initiation of Stage II (terms and conditions to be
memorialized formally as a

                                       3





separate agreement at the successful  conclusion of Stage I), will commence.  In
general,  Stage II and III are envisioned as described below. Details may change
as determined and agreed to by both parties.


Stage II:

IIa  A task force of personnel  from JRH, MII, etc. will be appointed to analyze
     and agree upon the most  effective  type of device  necessary to "scale-up"
     which will deliver MII's process.

     Any commercial  agreements that are acknowledged  will need to take account
     of  marketability  of the end product and this will be built into the Stage
     II agreement.


IIb  The  development  and   implementation  of  this  prototypical   device  or
     assemblage of devices will be directed  towards  replicating  the lab bench
     inactivation  model on a scale that will  accommodate  present daily volume
     production (i.e. 1200 liters).

Upon successful completion of Stage II, licensing of MII's process as previously
discussed will be implemented.

Stage III:  Licensing of MII's  technology to JRH for the  inactivation of viral
contaminants  in  bovine  serum as  manufactured  in both  JRH's  and  Filtron's
production facilities following terms and conditions to be mutually agreed to by
both parties.

It is  understood  that any release of  information  by MII (press,  scientific,
etc.) would be provided to JRH prior to release for approval of factual content.
It is further  understood  that  reciprocally,  the same prior  approval will be
afforded to MII prior to JRH making any informational release.



Medizone International, Inc.                             JRH Biosciences, Inc.

By:_________________________
By:_______________________

Name:_______________________
Name:_____________________


Title:______________________
Title:____________________





                                        4